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Abstract 
Background: Optimization of cardiac output (CO) has been evidenced to reduce postoperative complications and to 
expedite the recovery. Likewise, CO and other dynamic cardiac parameters can describe the systemic blood flow and 
tissue oxygenation state and can be useful in different clinical fields. This study aimed to validate the qCO monitor 
(Quantium Medical, Barcelona, Spain), a new device to estimate CO and other related parameters in a continuous, fully 
non-invasive way using advanced digital signal processing of impedance cardiography. 
Methods: The LiDCOrapidv2 (LiDCO Ltd, London, UK) was used to compare the performance of the qCO in 15 
patients during major surgery under general anesthesia. Full surgeries were recorded and cardiac output obtained by 
both devices was compared by using correlation and Bland-Altman analysis. 
Results: The Bland-Altman analysis showed sufficient agreement with a mean bias of -0.03 ± 0.71 L/min.  
Conclusions: The findings showed that both systems offered comparable values and thus the non-invasive 
measurement of CO with qCO is a promising, feasible method. Further investigation will be required to validate this 
new device against calibrated devices and outcome studies would also be highly recommended. 
Keywords: cardiac output, non-invasive hemodynamic monitoring, qCO, LiDCO, impedance cardiography, prediction 
probability. 
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Introduction 
Since Adolph Fick in 1870 [1] described the first method to estimate cardiac output (CO), its measurement 
is considered an important tool due to the fact that a great percentage of disorders are related to systemic 
hemodynamics. However, measuring CO is often omitted because of the complexity and risks involved in 
the invasive methods such as the Swan-Ganz catheter [2], [3]. Regardless, thanks to the development of 
new minimally- and non-invasive techniques, CO monitoring has been increasing during the last two 
decades. 
The classical thoracic bioimpedance cardiography [4] is based on the fact that the fluids on the thoracic 
compartment alters the body resistance to the electrical current. Therefore, variations derived from the 
cardiac cycle of the blood volume flow in the aorta are related to changes in impedance measurement. This 
impedance wave is recorded using 4 electrodes by applying a high-frequency current with a given amplitude 
and frequency; its first derivative (dZ/dt) is used to compute the stroke volume (SV) [5]. 
Some of the new technologies which have lately been developed are modifications to the classical thoracic 
bioimpedance measurement. The thoracic bioreactance technique detects phase shift changes in voltage, 
which depend on pulsatile flow [6], [7]. Electrical velocimetry uses the same principles of bioimpedance, 
but applying a modified equation based on the maximum rate of change of the impedance [8], [9]. Electrical 
bioimpedance using endotracheal electrodes is supposed to provide an improved signal (with reduced noise) 
although due to the proximity to the aorta placement, the system requires an arterial catheter and hence it 
is not a fully non-invasive method [10], [11]. 
Monitoring of stroke volume is useful in preventing hypo- and hyperperfusion during the so-called Goal-
Directed Therapy (GDT) [12]. This therapy determines the need for volume resuscitation and the fluid 
responsiveness. Other examples of possible clinical applications are the diagnosis and prognosis of 
disorders such as the cardiogenic, hypovolemic or septic shock, guiding cardiac drugs administration and 
preventing complications after surgery [13], [14]. 
Scientific evidence supports the correlation of advanced monitoring with a good tissue perfusion and better 
hemodynamic optimization. This improves patient outcome, reduces mortality rates and hospital costs. 
Therefore, continuous cardiac parameters are especially useful in some medical specialties such as 
anesthesiology, emergency care and cardiology [11]–[15] 
The qCO monitor analyses the thoracic impedance and uses advanced digital signal processing for 
estimating the SV and CO. This technology offers high reliability in rejecting artefacts for better 
reproducibility and accuracy compared to former impedance cardiography (ICG) techniques. 
The aim of this study was to test the performance of the qCO using the LiDCOrapid as a reference. The 
two devices can monitor the CO continuously, but with different methods. The qCO detects variations in 
the impedance, while LiDCOrapid processes the pressure waveform to estimate the CO [16]. 
Several studies report an improved outcome with the usage of LiDCOrapid to guide goal-directed fluid 
therapy after emergency laparotomy [17], a reduced length of hospital stay in colorectal surgery [18], and 
in high-risk abdominal and bariatric surgery [19]. Therefore, the aim of this study was to compare the 
behaviours of LiDCOrapid and the new qCO device during anaesthesia procedures in the operatory room. 
Materials and Methods 
Study Protocol 
Fifteen patients undergoing major surgery under general anesthesia at the Zhongshan Hospital in Shanghai 
were assessed in this observational study. Details of the patients and operations are reported in Table 1. 
Age ranged between 43 and 67 years, with a mean age of 58.9 ± 6.7 years and a mean body mass index of 
22.8 ± 2.6 kg/m².  
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Anesthesia was induced with TCI. The infusion rate of remifentanil was controlled by Minto's 
pharmacokinetic model [20] with 4 ng/ml as effect-site target concentration and the infusion rate of 
propofol was controlled by Schnider's pharmacokinetic model [21] with 3 µg/ml as effect-site target 
concentration. Rocuronium, a short-to-intermediate-term muscle relaxant, was administered before 
intubation. The rocuronium loading dose was 40 mg. 
 
Anesthesia was maintained with sevoflurane, remifentanil and boluses of fentanyl administered in doses of 
50 or 100 µg as needed. Additional maintenance doses of rocuronium were used in the form of 10 mg 
boluses. In some cases lidocaine, morphine, atropine or ephedrine were additionally administered.  
 
The surface electrodes (Ambu® BlueSensor for ECG) were used for the qCO monitor. The pressure 
waveform for LiDCOrapid was obtained with an arterial line. The recordings were assessed simultaneously 
during the complete procedure, from 3 minutes before induction of anesthesia to 3 minutes after the 
recovery.  
 
Sex (m:f) 9:6 
Age (years) 58.9 ± 6.7 
Height (m) 163.7 ± 6.8 
Weight (kg) 61.1 ± 9.1 
BMI (kg m-2) 22.8 ± 2.6 
  
Operative procedure No. of patients 
Mastectomy 1 
Carotid endarterectomy 1 
Cytoreductive surgery 1 
Gastrostomy 2 
Hepatectomy 2 
Nephrectomy 1 
Ovarian cystectomy 1 
Thyreoidectomy 1 
Uretescope lithotripsy 4 
Hysteroscopic Resection (TCRF) 1 
Table 1. Patient Characteristics. Age, Height, Weight and BMI are given as mean ± standard deviation. 
This observational study was conducted in compliance with the requirements of the Zhongshan Hospital 
Ethical Committee. Exclusion criteria were patients under eighteen years old and pregnant women. 
Different types of surgery were included in our study since the objective was the direct comparison between 
both monitors. 
Cardiac Output Calculation 
The qCO records the impedance cardiography (ICG) and electrocardiogram (ECG) by using 4 electrodes, 
with one pair injecting a constant current (400 μA RMS at 50 kHz), and a second pair of electrodes 
measuring the resulting voltage (Figure 1). The voltage is amplified and digitized with a sampling frequency 
of 1,000 Hz. The qCO monitor uses the information from the impedance curve (Z) to calculate different 
hemodynamic variables. 
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Figure 1 Location of the qCO electrodes [22] 
The ICG signal represents the changes of the thoracic impedance due to variations in the blood flow. In 
practice, the raw Z signal is transformed into the –dZ/dt waveform by using the first derivative to remark 
the inflection points of the raw Z signal. This signal is post-processed to increase its quality as shown in 
Figure 2. 
 
Figure 2 Impedance signal processing in the qCO monitor 
The most important characteristic points of the qCO impedance signal are their maxima (C) and their 
preceding minima (B), as observed in Figure 3. These points are associated to distinct physiological events 
within the systolic part of the cardiac cycle: B points are the downward deflection due to the contraction of 
the atria and C points are the major upward deflection occurring during systole [23]. In that sense, the R 
wave from the ECG signal is an important reference for detecting such events. The qCO algorithm locates 
these points, which relate to the stroke volume of the patient. The main problems arising from these point 
locations involve noise detection and movement of the patient, since the signals are highly sensitive. 
Different algorithms to prevent noise and artifacts are implemented in the qCO device. 
The ECG waveform reflects the changes in the electrical activity derived from the myocardium depolarizing 
and repolarizing during the cardiac cycle. This signal is used to calculate the heart rate (HR) and R-R 
interval (consecutive time between R waves which represent the ventricular depolarization). The mentioned 
waveforms are depicted in Figure 3.  
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Figure 3 Time relationship between the ECG, Z and -dZ/dt waveforms. The characteristic point of the -dZ/dt 
waveform is identified as B, which corresponds to the opening time of the aortic valve (identified as the local minima 
before the C point). The C is the maximum blood flow in the left ventricle. The X reveals the closing of aortic valve 
(identified as local minima after C point) 
 
Data Preparation  
The synchronization between both devices was ensured by annotating the exact start time given by the two 
devices. Data values of cardiac output were not taken into consideration when there was an instantaneous 
variation of either HR, CO or SV greater than 25% which was not justified from a clinical point of view. 
This led to a total rejection rate of < 2% for LiDCOrapid and < 1% for qCO. Two patients (one for 
gastrostomy and another one for cytoreductive surgery) were excluded due to excessive noise, and thus a 
total of thirteen patients remained to be considered for this study. To create the pairs of cardiac output 
values, each CO point from qCO was paired with the closest CO point by LiDCOrapid within a time 
difference of one second between both points. 
Statistical Analysis  
The qCO agreement with the LiDCOrapid’s signal was assessed using different statistical techniques: 
correlation and Bland-Altman analysis. 
A correlation analysis was conducted to estimate the relationship between the cardiac outputs calculated by 
the LiDCOrapid and qCO monitors. Correlation can show whether pairs of variables are related but a high 
correlation does not imply a good agreement between two methods. Bland-Altman analysis for repeated 
measurements per patient were used for the pool of patients to assess the agreement between qCO and 
LiDCOrapid. The Bland-Altman plot, also known as difference plot, is a method to compare two techniques 
(usually one of them as a reference) for the measurement of the same parameter. The correlation is shown 
by plotting the differences between the measurements produced by both methods against the mean value 
of such measurements. 
A linear mixed model with random effects was used to adjust for the interaction between the two methods 
and the time replicates of patients, resulting in a common standard deviation (SD) to calculate the limits of 
agreement (LOA) with its upper and lower limits determined by the mean difference between data from the 
reference and studied method ± 1.96 SD [24]–[26]. The percentage error was calculated as the ratio of 2SD 
of the bias to the mean CO and was considered clinically acceptable when it was 30% or less, as proposed 
by Critchley and Critchley [27], [28]. Before computing the Bland-Altman plot, according to Squara et al. 
[29], each recording should be divided into unchanging, increasing and decreasing periods and the 
description of a device can only be estimated on unchanging, stable periods. 
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Results 
Data from 13 patients, 8 males and 5 females were included into final analysis. Not a single patient suffered 
from any complication in the context of the present study. Blood loss, fluid administration and hypotension 
periods after induction were not included into our analysis. Figure 4 displays one of the cases. In this figure, 
it is visible that qCO and LiDCOrapid share a common overall trend. However, LiDCOrapid shows several 
sudden drops in cardiac output for which there is no reported clinical evidence and which are not followed 
by the qCO monitor. 
 
Figure 4 The cardiac output assessed by the qCO and the LiDCOrapid. The figure shows an example of a recording 
obtained with qCO and LiDCOrapid.  
Patient hemodynamic data are reported in Table 2. According to qCO, cardiac output ranged 4.5 ± 0.5 l/min, 
stroke volume 69.6 ± 8.8 ml/beat. According to LiDCOrapid, these values were 4.5 ± 0.7 l/min and 69.8 ± 
10.9 ml/beat. Heart rate was the same for both devices: 64.8 ± 7.5 bpm. Non-significant differences were 
observed between qCO and LiDCOrapid regarding those values.  
Surgery duration (min) 135.1 ± 59.63 
Cardiac Output (l/min) 4.5 ± 0.5 (qCO); 4.5 ± 0.7 (LiDCOrapid) 
Stroke Volume (ml/beat) 69.6 ± 8.8 (qCO); 69.8 ± 10.9 (LiDCOrapid) 
Heart Rate (bpm) 64.8 ± 7.5 (qCO and LiDCOrapid) 
Table 2. Hemodynamic characteristics. All values are presented as mean ± standard deviation.  
The operative procedures, whose type is also reported in Table 2, lasted 113 [88 200] minutes (median and 
25, 75-percentiles). A median of 3,557 [2,407 6,996] points (median and 25, 75-percentiles) were paired 
from qCO and LiDCO cardiac output. 
Correlation analysis showed no good indication of proportional bias (r²=0.3987, p<0.05). This analysis and 
the Bland-Altman plot are included in Figure 5 and Figure 6, respectively. The Bland-Altman plot compares 
the differences in CO values against the mean of the total measures of both methods, qCO and LiDCOrapid. 
In Figure 6, the black solid line represents the mean difference and the dotted lines represent the accepted 
limits of agreement (mean difference ± 2SD). The standard deviation has been corrected for the pooled data 
using two variances: that for repeated differences between the two methods on the same subject and that 
for the differences between the averages of the two methods across subjects. 
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Figure 5. Correlation analysis of the pool data. 
In this case, the Bland-Altman analysis shows a mean bias of -0.03± 0.71L/min. Upper and lower limits of 
agreement are 1.4 and -1.4, respectively. Percentage error was 29%, which is just below the recommended 
30% [27], [28]. The color bar ranges from a 0 to 1043 in logarithmic units, so the areas outside the limits 
of agreement are not relevant compared to the rest of the figure. 
 
Figure 6 Bland-Altman plot of comparing the differences in CO values against the mean of the total measures of qCO 
and LiDCOrapid. The color column indicates the number of points in each square. 
Discussion  
This study reports an initial validation of the new qCO device against the LiDCOrapid device with a mean 
bias of -0.03 ± 0.71 L/min. There is a reasonable amount of studies on the LiDCOrapid technology. In a 
study by Phan and colleagues [30], LiDCOrapid showed an increase of 41% after a fluid bolus 
measurement. When comparing the test device to thermodilution, the kappa statistic showed fair agreement 
of 0.28. After vasopressor administration, there was also significant variation in the change in cardiac 
output. Using Bland-Altman analysis, the precision of LiDCOrapid in comparison to thermodilution 
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showed minimal bias, but wide limits of agreement with percentage errors of 54.2%. In this study, other 
instruments were also tested against thermodilution with similar results. These findings indicated that 
LiDCOrapid, Vigileo Flotrac and Oesophageal Doppler Monitor (ODM) differ in their responses, do not 
always provide the same information as thermodilution and should not be used interchangeably to track 
cardiac output changes. 
Nordström and colleagues [31] compared ODM and LiDCOrapid for stroke volume (SV) optimization 
during colorectal surgery using fluid challenges. For 172 paired SV values, the overall correlation was 
r=0.39, and bias (limits of agreement) -28 [-91 35] ml, percentage error 70%. The ability of LiDCOrapid 
to track changes in SV compared to ODM was weak with a concordance rate of 80%, and a sensitivity and 
specificity of 48% and 81%, respectively, to detect a positive fluid challenge. 
Davies and colleagues [32] conducted a study where simultaneous reading of SV, stroke volume variation 
(SVV) and pulse pressure variation (PPV) from LiDCOrapid and FloTrac were taken in 20 patients and 
compared with ODM. The main conclusion was that SV measured by the FloTrac and LiDCOrapid systems 
does not correlate with the ODM, has poor concordance and a clinically unacceptable percentage error. 
However, SVV measured by the LiDCOrapid has clinical utility. 
Costa and colleagues [33] studied the level of agreement between cardiac output obtained by LiDCOrapid 
and continuous cardiac output (CCO) and intermittent cardiac output (ICC) obtained by the pulmonary 
artery catheter (PAC) in patients after liver transplantation. The performance of LiDCOrapid was moderate 
in detecting changes in ICO. 
The current study statistically describes the new qCO monitor. It therefore constitutes an initial validation 
of this new monitor. Today, clinicians can choose amongst a wide variety of less-invasive or non-invasive 
devices to calculate cardiac output. Each device consists on a proprietary software algorithm which 
processes different types of signals. However, several studies have demonstrated a lack of accuracy in these 
monitors [9], [13], [27], [30]–[33]. Quantium Medical qCO monitors is born from the intention of applying 
advanced signal processing techniques to bioimpedance signals in order to offer a totally non-invasive 
device to measure cardiac output. 
Our main finding is the acceptable percentage error of the qCO monitor compared to the LiDCOrapid 
system. It should be mentioned that several studies have previously demonstrated the validity of monitors 
using a technology similar to qCO in comparison to calibrated methods. The NICOM monitor (Cheetah 
Medical) [34] compared to thermodilution showed a mean bias of -0.81 with 95% limits of agreement of [-
3.54 +1.92]. Cardiac output by NICOM was also more precise than by thermodilution (precision of 
3.5±0.3% for NICOM versus 9.6±6.1% for thermodilution, p<0.001). 
In our study, the Bland-Altman plot between qCO and LiDCO shows that the majority of values adjusted 
to the agreement limits and the hot spots are distributed near zero (represented with the hottest colors in 
Figure 6). The mean bias is -0.03 and the limits of agreement are +1.4 and -1.4. Given the large sample size 
(56,456 total samples), this distribution of the points demonstrates a very low bias.  
In a similar study performed for the validation of electrical velocimetry (EV) with cardiac magnetic 
resonance imaging (CMR) as reference [35], the authors admitted an insufficient agreement and referred to 
a Bland-Altman plot with a mean bias of 1.2±1.4 l/min. This represents a higher mean bias and wider limits 
of agreement compared to the data published in the present article. Consequently, it is possible to affirm 
that nearly identical results can be provided from qCO and LiDCOrapid. 
Our study presents a number of limitations which must be considered. First, the observational protocol 
included a variety of operations and did not include exact measuring points. It is especially important to 
note that this variety of operations can imply different requirements in fluid management. Although this 
introduces a higher variability in our findings, it was useful to characterize the general behavior of the qCO 
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monitor. Nonetheless, one should recognize that this methodology might not provide sufficiently clean data 
to make perfect comparisons between technologies. 
This is also linked with the fact that segmentation into unchanged, increasing and decreasing periods was 
not possible. Some authors [29] have stated that the comparison and analysis of medical devices must be 
conducted during stable periods. However, the analysis of the trends in our recordings showed a lack of 
many unchanged periods and, therefore, the analysis of the bias was performed on all data and not only on 
the data with unchanging trend. At the same time, this implies an important limitation although it should 
also be noted that the purpose of this work was to compare the behavior of both instruments under the same 
varying conditions. 
As previously mentioned, LiDCOrapid is not a gold standard. Further studies against calibrated devices, 
such as the pulmonary artery catheter, will be required in order to complete the validation of the new qCO 
monitor. Moreover, in future studies, more protocolary procedures would be highly recommended. 
Outcome studies are also a powerful tool to take into account in order to validate the benefits of the usage 
of the qCO monitor. Furthermore, the implementation of more detailed protocols will also allow 
determination of the trending ability of changes between qCO and other standard technologies.  
Finally, future studies will need to include the analysis of the precision of the qCO device as reported in 
[36]. Precision is a major issue in clinical monitoring which has also been cited for other devices during the 
discussion but not analyzed for the case of the qCO. 
Conclusions 
In conclusion, the results suggest that cardiac output calculated with the qCO monitor is comparable to the 
values calculated by the LiDCOrapid monitor. In line with this and previous studies [22], [37],  the qCO 
has demonstrated a very low bias with the LiDCOrapid monitor in a variety of different situations. 
Future studies need to be performed to compare the qCO with calibrated devices in order to ensure a 
complete validation. Certainly, the availability and reliability of non-invasive cardiac output devices make 
cardiac output monitoring an attractive option for all clinical situations.  
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